• Explore /
  • Poster
  • / Enzalutamide versus abiraterone plus prednisolone before chemotherapy for Japanese castration-resistant prostate cancer patients: An investigator-initiated, multicenter, randomized controlled trial.

Enzalutamide versus abiraterone plus prednisolone before chemotherapy for Japanese castration-resistant prostate cancer patients: An investigator-initiated, multicenter, randomized controlled trial.

Abstract Poster

Authors

null

Kouji Izumi

Kanazawa University Hospital, Kanazawa, Japan

Kouji Izumi , Takashi Shima , Koji Mita , Yuki Kato , Manabu Kamiyama , Shogo Inoue , Nobumichi Tanaka , Seiji Hoshi , Takehiko Okamura , Yuko Yoshio , Hideki Enokida , Ippei Chikazawa , Noriyasu Kawai , Kohei Hashimoto , Takashi Fukagai , Kazuyoshi Shigehara , Shizuko Takahara , Yoshifumi Kadono , Atsushi Mizokami

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

UMIN000015529

Citation

J Clin Oncol 40, 2022 (suppl 6; abstr 122)

DOI

10.1200/JCO.2022.40.6_suppl.122

Abstract #

122

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Naoki Terada

First Author: Simon J. Crabb

First Author: Tatsuya Shimomura

First Author: Fred Saad